Cargando…

Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial

INTRODUCTION: The question of how to administer adequate chemotherapy to synchronise stereotactic body radiation therapy (SBRT) treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients with borderline resectable (BRPC) and locally advanced (LAPC) panc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Rong, Wang, Congfei, Huang, Xiaoxue, Lin, Qingliang, Huang, Daxin, Li, Xiao-Bo, Huang, Heguang, Xu, Benhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646341/ https://www.ncbi.nlm.nih.gov/pubmed/33154057 http://dx.doi.org/10.1136/bmjopen-2020-039900

Ejemplares similares

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial
por: Zheng, Rong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Intraoperative Radiation “Boost” to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report
por: Thomas, Tarita O., et al.
Publicado: (2018)

The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer
por: Luo, Xin, et al.
Publicado: (2023)

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
por: Ji, Xiaoqin, et al.
Publicado: (2022)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
por: Paiella, Salvatore, et al.
Publicado: (2021)

Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after pancreaticoduodenectomy
por: Huang, Jin-Can, et al.
Publicado: (2023)

The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
por: Hussien, Nervana, et al.
Publicado: (2022)

Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience
por: Lee, Hye In, et al.
Publicado: (2022)

The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer
por: Lin, Timothy, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation
por: Sutera, Philip, et al.
Publicado: (2018)

Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?
por: Pandé, Rupaly, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
por: Sutera, Philip A., et al.
Publicado: (2018)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study
por: Vitolo, Viviana, et al.
Publicado: (2019)

Observational study of surgical resection in small non-functional pancreatic neuroendocrine tumors: AS SEER-based study
por: Lin, Jiajing, et al.
Publicado: (2023)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection
por: Reddy, Abhinav V., et al.
Publicado: (2021)

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
por: Bijlani, Akash, et al.
Publicado: (2013)

One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review
por: Sutera, Philip Anthony, et al.
Publicado: (2017)

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
por: Lu, Changchang, et al.
Publicado: (2022)

Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer
por: He, Chaobin, et al.
Publicado: (2021)

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)
por: Gao, Suizhi, et al.
Publicado: (2019)

What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery
por: Acker, Gueliz, et al.
Publicado: (2023)

Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft
por: Huang, Jin-Can, et al.
Publicado: (2022)

Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
por: Holyoake, Daniel L.P., et al.
Publicado: (2016)

Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer
por: Chuong, Michael D., et al.
Publicado: (2022)

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy
por: Hill, Colin, et al.
Publicado: (2022)

Corrigendum: What if: a retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery
por: Acker, Gueliz, et al.
Publicado: (2023)

Prognostic Impact of Pretreatment Elevated and Normalized Carcinoembryonic Antigen Levels After Neoadjuvant Chemoradiotherapy in Resected Locally Advanced Rectal Cancer Patients
por: Song, Jianyuan, et al.
Publicado: (2021)

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

The Clinical Outcomes, Prognostic Factors and Nomogram Models for Primary Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
por: Luo, Li-Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gf3h70veqrja3rhqnjidb6jap7